Category: Finance
Guggenheim raised the price target for Blueprint Medicines from $130 to $138, maintaining a buy rating. Other analysts have also increased their price targets, with a consensus rating of Moderate Buy and an average price target of $120. The company reported earnings of ($0.80) per share, beating estimates, and revenue of $138.20 million, up 139.9% year-over-year. Insider trading activity has seen significant share sales, and institutional investors have adjusted their positions in the company.
Keywords: Blueprint Medicines, stock analysis, price target
Update At: 8/5/2024